European regulators recommended a subcutaneous formulation for a key anti-CD38 therapy, offering clinicians and patients more flexible administration options for multiple myeloma.
Verywell Health on MSN
IV vs. subcutaneous cancer therapies: What’s the difference?
Medically reviewed by Marla Anderson, MD Key Takeaways IV therapy delivers cancer medicine directly into a vein and often ...
Patients with non-squamous non-small cell cancer may achieve similar outcomes with a subcutaneous formulation of the immunotherapy toripalimab as with IV administration.
French drugmaker Sanofi said on Friday the European Medicines Agency has recommended the approval of a subcutaneous version ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results